Strata Skin Sciences Sales Decline
Strata Skin Sciences (NASDAQ:SSKN), a medical technology firm specializing in dermatology devices, reported its second quarter 2025 earnings on August 13, 2025. The company reported GAAP revenue of $7.7 million, missing analyst expectations of $8.56 million and down from $8.4 million in Q2 2024. GAAP earnings per share were negative $0.60, below estimates for a negative $0.29 result, and reflecting a significant deterioration from negative $0.03 per share in Q2 2024. Results highlighted operational weakness, with both recurring and equipment revenue dropping, while gross profit and profitability measures also declined. Although the quarter included a major reimbursement win that could increase XTRAC’s long-term market opportunity, the short-term financial performance fell short of expectations.
Source: Analyst estimates for the quarter provided by FactSet.
Strata Skin Sciences is a medical device company serving dermatologists and clinics worldwide. Its key products include excimer laser systems (XTRAC and Pharos), lamp-based phototherapy systems (VTRAC), and the TheraClearX acne treatment system. These technologies are used to treat common skin conditions such as psoriasis, vitiligo, and acne.
Source Fool.com
